Neutron source applicability evaluation method and device for BNCT, and electronic equipment

By constructing three-dimensional models and Monka simulations, the applicability of neutron sources is evaluated, and the problem of the difference in neutron beam energy and flux affecting BNCT treatment is solved, and reasonable treatment plans are provided for different tumors, which improves the treatment effect.

CN119049581AInactive Publication Date: 2024-11-29HUAPENG NEUTRON TECH (HANGZHOU) CO LTD

Patent Information

Application Number
CN202411536675.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-31
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The lack of an existing neutron source applicability evaluation system has led to the lack of BNCT treatment effect due to differences in neutron beam energy and flux, making it difficult to formulate reasonable treatment plans for different types of tumors.

Method used

By constructing a three-dimensional model of the target object, the material group and boron concentration of the voxel grid were obtained, combined with Monka simulation data for simulation, the equivalent dose was calculated, and the applicability of neutron sources was evaluated based on the average absorbed dose and tumor uniformity index. .

Benefits of technology

It provides a comprehensive method to evaluate the therapeutic effect of neutron sources, which is compatible with organs and tumors, helps to develop reasonable treatment plans, and improves the accuracy of neutron sources' applicability assessment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119049581A_ABST
    Figure CN119049581A_ABST
Patent Text Reader

Abstract

The invention relates to a neutron source applicability evaluation method and device for a BNCT and electronic equipment, and relates to the technical field of BNCTs. The method solves the defect that in the prior art, the applicability of a neutron source cannot be evaluated, and the scheme specifically comprises the steps that a three-dimensional model is constructed according to a CT image of a target object, and a target area is determined in the three-dimensional model; obtaining a material group type and a boron concentration of each voxel grid in the three-dimensional model, and determining Monte Carlo simulation data in combination with the distribution condition of the voxel grids; monte Carlo simulation is carried out according to the Monte Carlo simulation data and simulation parameters of a neutron source, and the equivalent dose of each voxel grid in the target area is obtained through a simulation result; and based on the equivalent dose of the voxel grid, determining an average absorbed dose and a tumor uniformity index of all organs at risk in the target area, and obtaining an applicability evaluation index according to the average absorbed dose and the tumor uniformity index.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of BNCT, and in particular to a method and device for evaluating the suitability of a neutron source for BNCT, and an electronic device. Background Art

[0002] Boron Neutron Capture Therapy (BNCT) is a cancer treatment technology. Specifically, boron drugs are concentrated in the tumor cells of the target object, and neutron source irradiation is used to make boron ions capture neutrons to produce 10B(n,α)7Li reaction to produce heavy ions. The range of heavy ions is comparable to the cell scale, and can kill cancer cells accurately and efficiently at the cell scale.

[0003] Currently, neutron sources used for BNCT mainly include reactor-based neutron sources and accelerator-based neutron sources. Figure 1 This is the corresponding relationship between neutron energy and neutron flux of three different neutron sources. Figure 1 It can be seen that different neutron sources, such as different neutron source types or different energy accelerators, will affect the energy and flux of the neutron beam. Therefore, even if the same type of neutron source is used, the performance of the neutron beam is different. The difference in neutron beams will directly affect the therapeutic effect of BNCT. In addition, different types of tumors are distributed at different depths in the tissue, and tumors at different depths require neutron beams of different energies. High-energy neutron beams are required for deep tumors, and low-energy neutron beams are required for superficial tumors. It can be seen that different neutron sources have different applicability.

[0004] However, there is currently a lack of an evaluation system for the applicability of different types of neutron sources. Based on this, it is necessary to provide a neutron source applicability evaluation method for BNCT to provide an effective reference for formulating a reasonable treatment plan. Summary of the invention

[0005] The embodiments of the present application provide a method and device for evaluating the suitability of a neutron source for BNCT, and an electronic device, so as to at least solve the problem in the related art that the suitability of different neutron sources cannot be evaluated.

[0006] In a first aspect, an embodiment of the present application provides a method for evaluating the suitability of a neutron source for BNCT, comprising: constructing a three-dimensional model based on the CT image of the target object, and determining a target area in the three-dimensional model; Obtaining the material group and boron concentration of each voxel grid in the three-dimensional model, and determining Monte Carlo simulation data in combination with the distribution of the voxel grid; Performing Monte Carlo simulation according to the Monte Carlo simulation data and simulation parameters of the neutron source, and obtaining the equivalent dose of each voxel grid in the target area through the simulation result; The average absorbed dose and the tumor homogeneity index of all organs at risk in the target area are determined based on the equivalent dose of the voxel grid, and the suitability assessment index is obtained according to the average absorbed dose and the tumor homogeneity index.

[0007] Optionally, obtaining the applicability evaluation index according to the average absorbed dose and the uniformity index is performed in the following manner:

[0008] Among them, Ec is the evaluation index, is the weight coefficient of the average absorbed dose, is the average absorbed dose, is the weight coefficient of the tumor homogeneity index, Tumor homogeneity index.

[0009] Optionally, the determining the average absorbed dose of all organs at risk and the tumor homogeneity index in the target area based on the equivalent dose of the voxel grid comprises: Obtaining a dose volume histogram according to the equivalent dose of each voxel grid in the target area; Determining dose absorption data of each organ at risk and tumor in the target area according to the dose volume histogram; The average absorbed dose is determined based on the dose absorption data of each organ at risk and the equivalent dose of a voxel grid in the organ at risk, and the tumor homogeneity index is determined according to the dose absorption data of the tumor.

[0010] Optionally, the dose absorption data of each organ at risk includes the maximum absorbed dose of each organ at risk; and determining the average absorbed dose according to the dose absorption data of each organ at risk includes: In response to the maximum absorbed doses of all the organs at risk being less than the preset limit of the corresponding organ, the absorbed dose of the organ at risk is obtained according to the equivalent dose of the voxel grid in any of the organs at risk, and the average absorbed dose is obtained according to the absorbed doses of all the organs at risk.

[0011] Optionally, the dose absorption data of the tumor includes dose values ​​corresponding to a low volume fraction, a median volume fraction, and a high volume fraction, and determining the tumor uniformity index according to the dose absorption data of the tumor includes: Obtaining a dose value difference corresponding to the low volume fraction and the high volume fraction; The ratio of the dose value difference to the dose value corresponding to the median volume fraction is used as the tumor uniformity index.

[0012] Optionally, the simulation result includes a dose rate of a target component in any voxel grid, and the target components include boron, nitrogen, hydrogen and photons; and obtaining the equivalent dose of each voxel grid in the target area through the simulation result includes: Performing equivalent dose processing on the dose rate of the target component to obtain a total dose rate of the voxel grid; The duration of radiation is obtained based on the prescription dose and the total dose rate of the voxel grid within the tumor region in the target area; The equivalent dose of each voxel grid is acquired according to the radiation duration and the total dose rate.

[0013] Optionally, the dose rate of the target component is subjected to equivalent dose processing to obtain the total dose rate of the voxel grid, according to the following formula: Where D is the total dose rate, DB,ppm is the boron dose rate, DN is the nitrogen dose rate, DH is the hydrogen dose rate, and Dγ is the photon dose rate; CBE is the composite biological effect factor, RBEN is the relative biological effect factor determined based on the nitrogen absorption dose rate, RBEH is the relative biological effect factor determined based on the hydrogen absorption dose rate, and RBEγ is the relative biological effect factor determined based on the photon absorption dose rate; Represents the time-dependent boron concentration in tissues.

[0014] Optionally, obtaining the material group and boron concentration of each voxel grid in the three-dimensional model includes: Determine whether the current voxel grid is within the target area; If it is in the target area, obtaining the corresponding material group according to the position of the current voxel grid in the target area, and determining the boron concentration corresponding to the material group according to the pharmacokinetic characteristics of the boron drug of the target object; If it is outside the target area, the material group of the voxel grid is determined according to the CT value of the CT image corresponding to the voxel grid, and the relative boron concentration is determined based on the material category.

[0015] Optionally, the method further comprises: performing pharmacokinetic simulation according to boron drug data and individual physiological parameters of the target subject to obtain pharmacokinetic curves in different material groups; The pharmacokinetic characteristics of the corresponding tissue category are obtained according to the pharmacokinetic curve.

[0016] In a second aspect, an embodiment of the present application provides a neutron source suitability assessment device for BNCT, the device comprising: A construction module, used to construct a three-dimensional model according to the CT image of the target object, and determine the target area in the three-dimensional model; A determination module, used to obtain the material group and boron concentration of each voxel grid in the three-dimensional model, and determine Monte Carlo simulation data in combination with the distribution of the voxel grid; An acquisition module, used for performing Monte Carlo simulation according to the Monte Carlo simulation data and simulation parameters of the neutron source, and obtaining the equivalent dose of each voxel grid in the target area through the simulation result; An evaluation module is used to determine the average absorbed dose and tumor homogeneity index of all organs at risk in the target area based on the equivalent dose of the voxel grid, and obtain a suitability evaluation index according to the average absorbed dose and the tumor homogeneity index.

[0017] Optionally, the evaluation module obtains the applicability evaluation index according to the average absorbed dose and the uniformity index in the following manner:

[0018] Among them, Ec is the evaluation index, is the weight coefficient of the average absorbed dose, is the average absorbed dose, is the weight coefficient of the tumor homogeneity index, Tumor homogeneity index.

[0019] Optionally, the evaluation module includes: A first determining unit, configured to obtain a dose volume histogram according to an equivalent dose of each voxel grid in the target area; A second determination unit is used to determine dose absorption data of each organ at risk and tumor in the target area according to the dose volume histogram; The third determination unit is used to determine the average absorbed dose according to the dose absorption data of each organ at risk, and to determine the tumor homogeneity index according to the dose absorption data of the tumor.

[0020] Optionally, the dose absorption data of each organ at risk includes the maximum absorbed dose of each organ at risk; and the third determination unit is specifically configured to: In response to the maximum absorbed doses of all the organs at risk being less than a preset limit value of the corresponding organ, the average absorbed dose is obtained according to the maximum absorbed doses of all the organs at risk.

[0021] Optionally, the dose absorption data of the tumor includes dose values ​​corresponding to a low volume fraction, a median volume fraction, and a high volume fraction, and the third determination unit is specifically used to: Obtaining a dose value difference corresponding to the low volume fraction and the high volume fraction; The ratio of the dose value difference to the dose value corresponding to the median volume fraction is used as the tumor uniformity index.

[0022] Optionally, the simulation result includes a dose rate of a target component in any voxel grid, and the target component includes boron, nitrogen, hydrogen and photons; and the acquisition module includes: a fifth determination unit, configured to perform equivalent dose processing on the dose rate of the target component to obtain a total dose rate of the voxel grid; A first acquisition unit is used to acquire the radiation duration according to the prescription dose and the total dose rate of the voxel grid in the tumor area in the target area; The second acquisition unit is used to acquire the equivalent dose of each voxel grid according to the radiation duration and the total dose rate.

[0023] Optionally, when the fifth unit performs equivalent dose processing on the dose rate of the target component to obtain the total dose rate of the voxel grid, it is performed according to the following formula: Where D is the total dose rate, DB,ppm is the boron dose rate, DN is the nitrogen dose rate, DH is the hydrogen dose rate, and Dγ is the photon dose rate; CBE is the composite biological effect factor, RBEN is the relative biological effect factor determined based on the nitrogen absorption dose rate, RBEH is the relative biological effect factor determined based on the hydrogen absorption dose rate, and RBEγ is the relative biological effect factor determined based on the photon absorption dose rate; Represents the time-dependent boron concentration in tissues.

[0024] Optionally, the determining module includes: A judging unit, used to judge whether the current voxel grid is within the target area; A first determination unit, configured to, when the determination unit determines that the current voxel grid is within the target region, obtain a corresponding material group according to the position of the current voxel grid in the target region, and determine a boron concentration corresponding to the material group according to the pharmacokinetic characteristics of the boron drug of the target object; The second determination unit is used to determine the material group of the voxel grid according to the CT value of the CT image corresponding to the voxel grid if the judgment unit determines that the current voxel grid is outside the target area, and determine the relative boron concentration based on the material category.

[0025] Optionally, the device further comprises: An acquisition module is used to perform pharmacokinetic simulation based on boron drug data and individual physiological parameters of the target subject to obtain pharmacokinetic curves in different material groups; The pharmacokinetic characteristics of the corresponding tissue category are obtained according to the pharmacokinetic curve.

[0026] In a third aspect, an embodiment of the present application provides an electronic device, the electronic device comprising: Memory, processor, and A computer program stored in the memory and executable on the processor, wherein when the processor executes the computer program, the method for evaluating the suitability of a neutron source for BNCT as provided in the first aspect above is implemented.

[0027] In a fourth aspect, an embodiment of the present application provides a computer-readable storage medium having a computer program stored thereon, which, when executed by a processor, implements the neutron source suitability assessment method for BNCT as described in the first aspect above.

[0028] The neutron source suitability assessment method and device, and electronic equipment for BNCT provided in the embodiments of the present application have at least the following technical effects.

[0029] The suitability evaluation index is obtained based on the average absorbed dose and tumor uniformity index. The suitability evaluation index is compatible with the impact of neutron sources on organs at risk and tumors, and comprehensively evaluates the treatment effect of the neutron source scheme. Among them, the smaller the suitability evaluation index, the better the average absorbed dose of organs at risk and the uniformity of tumor absorbed dose, and the better the suitability of the neutron source. In this way, an evaluation method for the suitability of neutron sources for BNCT is constructed, and the applicability advantages of different neutron sources in application are analyzed, providing a theoretical basis for formulating reasonable treatment plans.

[0030] Details of one or more embodiments of the present application are set forth in the following drawings and description to make other features, objects, and advantages of the present application more readily apparent. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings: Figure 1 This is a graph showing the correspondence between neutron energy and neutron flux for three different neutron sources; Figure 2 is a flow chart of a method for evaluating the suitability of a neutron source for BNCT according to an exemplary embodiment; Figure 3 According to an exemplary embodiment, a CT image of a target object is shown; Figure 4 is based on Figure 3 Schematic diagram of the three-dimensional model constructed from the CT image shown; Figure 5 is a pharmacokinetic curve diagram according to an exemplary embodiment; Figure 6~Figure 8 is a DVH diagram of organs at risk and tumors under different neutron sources according to an exemplary embodiment; Fig. 9 is a schematic diagram of an isodose curve in a CT image according to an exemplary embodiment; Fig.10 is a flow chart of a method for evaluating the suitability of a neutron source for BNCT according to another exemplary embodiment; Fig.11 is a block diagram of a neutron source suitability assessment device for BNCT according to an exemplary embodiment; Fig.12 is a block diagram of an electronic device according to an exemplary embodiment. DETAILED DESCRIPTION

[0032] In order to make the purpose, technical solutions and advantages of the present application clearer, the present application is described and illustrated below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not intended to limit the present application. Based on the embodiments provided in the present application, all other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present application.

[0033] Obviously, the drawings described below are only some examples or embodiments of the present application. For ordinary technicians in this field, the present application can also be applied to other similar scenarios based on these drawings without creative work. In addition, it can also be understood that although the efforts made in this development process may be complicated and lengthy, for ordinary technicians in this field related to the content disclosed in this application, some changes in design, manufacturing or production based on the technical content disclosed in this application are just conventional technical means, and should not be understood as insufficient content disclosed in this application.

[0034] Reference to "embodiments" in this application means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those of ordinary skill in the art that the embodiments described in this application may be combined with other embodiments without conflict.

[0035] Unless otherwise defined, the technical terms or scientific terms involved in this application should be understood by people with ordinary skills in the technical field to which this application belongs. The words "one", "a", "a", "the" and the like involved in this application do not indicate a quantity limitation, and may indicate the singular or plural. The terms "include", "comprise", "have" and any of their variations involved in this application are intended to cover non-exclusive inclusions; for example, a process, method, system, product or device that includes a series of steps or modules (units) is not limited to the listed steps or units, but may also include steps or units that are not listed, or may also include other steps or units inherent to these processes, methods, products or devices. The words "connect", "connected", "coupled" and the like involved in this application are not limited to physical or mechanical connections, but may include electrical connections, whether direct or indirect. The "multiple" involved in this application refers to two or more. "And / or" describes the association relationship of associated objects, indicating that there may be three relationships, for example, "A and / or B" can mean: A exists alone, A and B exist at the same time, and B exists alone. The character " / " generally indicates that the objects before and after are in an "or" relationship. The terms "first", "second", "third", etc. involved in this application are only used to distinguish similar objects and do not represent a specific ordering of the objects.

[0036] In the first aspect, the embodiment of the present application provides a method for evaluating the suitability of a neutron source for BNCT, which is used to evaluate the suitability of different neutron sources, so as to provide a reference for rationally formulating a treatment plan. It should be noted that in the embodiment of the present application, a neutron source application scheme is specifically simulated to evaluate the suitability of the neutron source. Among them, the application scheme includes the type of neutron source and the operating conditions of the neutron source. For different neutron source equipment, after the proton energy is determined, the characteristics of the energy spectrum are basically determined. For example, the neutron energy generated by a 30MeV cyclotron is up to 28MeV, but the neutron energy generated by a 2.8MeV proton linear accelerator is less than 1MeV. The same neutron source equipment uses different beam shapers, and the neutron energy spectrum produced will be different.

[0037] Figure 2is a flow chart of the neutron source suitability assessment method for BNCT, such as Figure 2 As shown, the method includes: Step S201: construct a three-dimensional model according to the CT image of the target object, and determine the target area in the three-dimensional model.

[0038] The construction of a three-dimensional model provides a simulation basis for the subsequent scheme evaluation method. Among them, the CT image (also known as Computed Tomography) is an image of the cross-section of the target object, such as Figure 3 According to an exemplary embodiment, a CT image of a target object is shown. The three-dimensional shape of the target object can be determined by a plurality of sequentially arranged CT images of the target object, thereby constructing a three-dimensional model. Optionally, a 3D slicer medical image segmentation tool is used to construct a three-dimensional model based on the CT image of the target object. For example, Figure 4 is based on Figure 3 Schematic diagram of the three-dimensional model constructed from the CT images shown.

[0039] CT images contain contour information and location information of different tissues and organs such as tumors or organs at risk. The target area position of the treatment plan can be obtained through CT images. As an example, the target area manually outlined by the user on the CT image is obtained. An RTSTRUCT file containing target area information is created based on the target area on the CT image. MATLAB is used to read the RTSTRUCT file to parse the boundary of the defined target area, so as to determine the position of the target area boundary in the CT image, that is, to obtain the target area position. Furthermore, the target area is determined in the three-dimensional model based on the target area position on the CT image.

[0040] Step S202: Obtain the material group and boron concentration of each voxel grid in the three-dimensional model, and determine Monte Carlo simulation data based on the distribution of the voxel grid.

[0041] Voxel grids are the basic building blocks of a 3D model. Voxel grids are arranged along three mutually perpendicular directions (i.e., the x-axis, y-axis, and z-axis in a 3D coordinate system). Different voxel grids may correspond to different tissues (e.g., skin, blood, tumors, etc.). The concentration of boron may be different in different tissues. The accuracy of the boron concentration in the voxel grid directly affects the accuracy of the Monte Carlo simulation.

[0042] In this embodiment, step S202 specifically includes: determining whether the current voxel grid is within the target area, and determining the corresponding material group type according to the positional relationship between the current voxel grid and the target area.

[0043] If it is determined that the current voxel grid is outside the target area, the material group of the voxel grid is determined according to the CT value of the CT image corresponding to the voxel grid, and the relative boron concentration is determined based on the material category.

[0044] The CT value of the voxel grid represents the attenuation value of X-rays after passing through tissue and being absorbed. Different material groups correspond to different CT values. The CT value of each substance is determined according to the following formula: in, is the water linear attenuation coefficient, is the linear attenuation coefficient of the material, is the CT value of the substance.

[0045] Based on the above formula, the CT value corresponding to each voxel grid can be converted into the linear attenuation coefficient of the corresponding material, so as to find the material group of the voxel grid according to the corresponding relationship between the material group and the linear attenuation coefficient of the material, and then determine the boron concentration corresponding to the material group.

[0046] If it is determined that the current voxel grid is in the target area, the corresponding material group is obtained according to the position of the current voxel grid in the target area, and the boron concentration corresponding to the material group is determined according to the pharmacokinetic characteristics of the target object boron drug.

[0047] Since the target region may actually include both tumors and organs at risk, when the current voxel grid is determined to be within the target region, it indicates that the voxel grid may be a tumor region or a organ at risk region. Optionally, the material group class corresponding to the current voxel grid is obtained by user input, for example, a doctor determines the material group class corresponding to the current voxel grid in combination with a CT image and inputs it.

[0048] Moreover, when the voxel grid is located within the target area, the boron concentration of the voxel grid needs to be determined in combination with the individual characteristics of the target object, so as to improve the accuracy of the subsequent Monte Carlo simulation data and optimize the simulation results. Here, the individual characteristics of the target object are specifically represented by pharmacokinetic characteristics. For example, if the material group of the voxel grid is determined to be blood, the boron concentration corresponding to the voxel grid is determined according to the pharmacokinetic characteristics in the blood. For another example, if the material group of the voxel grid is determined to be a tumor, the boron concentration corresponding to the voxel grid is determined according to the pharmacokinetic characteristics in the tumor.

[0049] Based on the above, before step S202, the evaluation method further includes: obtaining the pharmacokinetic characteristics of the target boron drug.

[0050] Optionally, pharmacokinetic simulation is performed based on boron drug data and individual physiological parameters of the target subject to obtain pharmacokinetic curves in different tissue categories, and the pharmacokinetic characteristics of the corresponding tissue category are obtained based on the pharmacokinetic curves.

[0051] Figure 5 is a pharmacokinetic curve diagram according to an exemplary embodiment, combined with Figure 5 As shown in Figure 1, the pharmacokinetic curve shows the metabolism of the drug in the target subject over time, with individual differences and tissue category differences. By constructing a pharmacokinetic curve, the pharmacokinetic characteristics of different tissue categories of the target subject can be accurately captured.

[0052] Among them, boron drug data include: plasma separation fraction, drug protein binding rate, and renal clearance rate. Individual physiological parameters include but are not limited to: age, weight, race, metabolic function parameters, and disease progression parameters. Pharmacokinetic simulation can be performed using PK-Sim (Pharmacokinetic Simulator) software. For example, an open two-compartment model is constructed to obtain the plasma boron concentration-time curve and the tumor boron concentration-time curve. In this way, the drug distribution and drug metabolism in different tissues of the target object are obtained, thereby obtaining the pharmacokinetic characteristics (such as boron metabolism peak) that reflect the individual characteristics of the target object.

[0053] In addition, by establishing a pharmacokinetic curve, a reasonable irradiation window time is provided. Based on the peak value of boron concentration in different tissue types, an irradiation window covering the peak stage is formulated, which improves the treatment effect on the one hand and avoids damage to the tissues of endangered organs on the other.

[0054] After determining the material category and boron concentration of the voxel grid, the Monte Carlo simulation data is obtained in combination with the distribution of the voxel grid in the three-dimensional model. The Monte Carlo simulation data includes material cards, grid cell cards, lattice cards, counting cards, and input cards. Here, the distribution of the voxel grid refers to the arrangement position of each voxel grid in the target area. According to the distribution of the voxel grid and the material category of each voxel grid, the lattice card and grid cell card in the Monte Carlo simulation data are determined.

[0055] Step S202 determines the material category and boron concentration of the voxel grid more accurately and individually by distinguishing the voxel grids inside and outside the target area, so as to fit the actual situation of the target object and optimize the accuracy of the subsequent Monte Carlo simulation. Among them, the material group classification is refined for the voxel grid in the target area to distinguish the material groups that may be covered by the target area. At the same time, the pharmacokinetic characteristics are combined with the individual differences of the target object, so as to achieve accurate program evaluation for different objects.

[0056] Step S203: Perform Monte Carlo simulation based on the Monte Carlo simulation data and the simulation parameters of the neutron source, and obtain the equivalent dose of each voxel grid in the target area through the simulation results.

[0057] When a neutron source is in use, its irradiation effect is not only affected by the type of neutron source, but also by the operating conditions of the neutron source. Even for neutron sources of the same type, the operating conditions (such as proton energy, beam shaper used by the neutron source) are different, and the neutron beam energy spectrum emitted by the neutron source is different. Therefore, in the embodiment of the present application, it is also necessary to consider the simulation parameters of the neutron source to simulate the operating conditions of the neutron source. Among them, the simulation parameters of the neutron source include the type of neutron source, the neutron energy, flux and irradiation angle information of the neutron source, so as to simulate the actual irradiation process of the neutron source, thereby accurately evaluating the application scheme of the current neutron source.

[0058] Optionally, Monte Carlo simulation is performed using PHITS software, and the simulation directly obtained by Monte Carlo simulation includes the dose rate of the target component in any voxel grid, and the target components include boron, nitrogen, hydrogen and photons. At this time, the equivalent dose of each voxel grid in the target area is obtained through the simulation results in step S203, including: Step S2031 : performing equivalent dose processing on the dose rate of the target component to obtain the total dose rate of the voxel grid.

[0059] The dose rate of the target component is processed by equivalent dose according to the following formula to obtain the total dose rate of the voxel grid: (1) Where D is the total dose rate, D B,ppm is the dose rate per unit boron concentration, D N is the nitrogen dose rate, D H is the hydrogen dose rate, D γ is the photon dose rate; CBE is the composite biological effect factor, RBE N is the relative biological effect factor determined based on the nitrogen absorbed dose rate, RBE H is the relative biological effect factor determined based on the hydrogen absorption dose rate, RBE γ is the relative biological effect factor determined based on the photon absorbed dose rate; Represents the time-dependent boron concentration in tissues, obtained through pharmacokinetic curves.

[0060] Step S2032: Obtain the radiation duration according to the prescription dose and the total dose rate of all voxel grids in the tumor area.

[0061] Specifically, in step S2031, the total dose rate of each voxel grid in the target area is obtained, and the tumor area is determined in the target area, so as to obtain the sum of the total dose rates of all voxel grids in the tumor area, that is, the total dose rate of the tumor area. Optionally, the radiation duration is determined in the following manner: (2) Among them, T is the radiation duration; Dp is the prescription dose, which represents the minimum dose that is lethal to cancer cells; Dtotal is the total dose rate in the tumor area.

[0062] Step S2033: Obtain the equivalent dose of each voxel grid according to the radiation duration and the total dose rate.

[0063] After the radiation duration is determined, the equivalent dose of each voxel grid is determined according to the product of the dose rate of each voxel grid and the radiation duration.

[0064] In this way, the dose of the target to the tumor area and the organ at risk can be obtained. For example, the dose of the organ at risk can be obtained by the following method: (3) Among them, D OAR is the absorbed dose to the organ at risk, D rate is the dose rate to the organ at risk and T is the duration of radiation.

[0065] Alternatively, the dose rate of each voxel grid in the organ at risk is first obtained according to the product of the dose rate of each voxel grid in the organ at risk and the radiation time, and then the dose of the organ at risk is obtained by summing the doses of the voxel grids in the organ at risk.

[0066] See again Figure 2 After obtaining the equivalent dose of each voxel grid in the target area in step S203, the method further includes: Step S204: determine the average absorbed dose and tumor homogeneity index of all organs at risk in the target area based on the equivalent dose of the voxel grid, and obtain a suitability assessment index according to the average absorbed dose and the tumor homogeneity index.

[0067] Among them, the average absorbed dose of organs at risk represents the dose absorption of different organs at risk, reflecting the impact of the neutron source on each organ at risk; the tumor uniformity index represents the uniformity of the tumor. The better the tumor uniformity, the better the lethal effect of neutron source irradiation on cancer cells.

[0068] Optionally, in step S204, the average absorbed dose of each organ at risk and the tumor uniformity index are obtained, which is specifically achieved by the following steps: Step S2041 : obtaining a dose-volume histogram according to the equivalent dose of each voxel grid in the target area.

[0069] Step S2042: Determine the dose absorption data of each organ at risk and tumor in the target area according to the dose volume histogram.

[0070] Step S2043: determining an average absorbed dose based on the dose absorption data of each organ at risk and the equivalent dose of the voxel grid in the organ at risk, and determining a tumor homogeneity index according to the dose absorption data of the tumor.

[0071] Dose and Volume Histogram (DVH) is the statistical analysis result of the relative volume of discrete dose sampling points, which shows the relationship between dose and volume. Figure 6~Figure 8 is a DVH diagram of organs at risk and tumors under different neutron sources according to an exemplary embodiment, such as Figure 6~Figure 8 As shown in the figure, the DVH diagrams of different organs at risk and tumors are determined according to the grouping of different tissue categories. In addition, different neutron source conditions have different effects on the same organs at risk or the same tumor. Specifically, the energy spectra of neutron beams generated under different neutron source conditions are different, and the effects of neutron beams with different energy spectra on the same tissue are different. Therefore, the DVH diagram can reflect the differences in irradiation effects of different neutron source conditions.

[0072] The method shown in step S203 above can obtain the dose absorption data of different organs at risk and tumor areas in the target area, and the DVH of the target area can be obtained by grouping statistics. The differential volume histogram (dDVH) can be obtained by grouping statistics of the target area, and the cumulative dose volume histogram (cDVH) can be obtained by integrating the dDVH. The prescription dose received by the corresponding volume fraction can be obtained from the cumulative dose volume histogram, and then the coverage of the target area and the dose to the organs at risk can be evaluated. In addition, the minimum absorbed dose, average absorbed dose and maximum absorbed dose of the organs at risk can be obtained according to the DVH diagram analysis.

[0073] In step S2042, the dose absorption data of the organs at risk include the minimum absorbed dose, average absorbed dose and maximum absorbed dose of each organ at risk. Among them, step S2043 of obtaining the average absorbed dose specifically includes: In response to the maximum absorbed doses of all organs at risk being less than the preset limit of the corresponding organ, the absorbed dose of any organ at risk is obtained according to the equivalent dose of the voxel grid in the organ at risk, and the average absorbed dose is obtained according to the absorbed doses of all organs at risk. Specifically, the average absorbed dose is obtained in the following manner: (4) is the average absorbed dose of all organs at risk, n is the number of organs at risk, D OAR,i is the absorbed dose of the i-th organ at risk in the target area, i is the number of organs at risk. OAR,i Obtained according to the above formula (3).

[0074] In step S2042, the dose absorption data of the tumor includes dose values ​​corresponding to the low volume fraction, the median volume fraction, and the high volume fraction. The dose values ​​corresponding to different volume fractions indicate that the dose of the volume fraction is greater than or equal to the critical value. Taking the low volume fraction as 5% as an example, the dose value D corresponding to the low volume fraction is 5% Indicates that the dose of 5% volume fraction is greater than or equal to the dose value D 5% .

[0075] There is no specific limitation on the specific values ​​of the low volume fraction, the median volume fraction and the high volume fraction. Preferably, the larger the span of the three volume fractions, the better. As an optional method, in the following, the low volume fraction is selected as 1%, the median volume fraction is selected as 50%, and the high volume fraction is selected as 99%.

[0076] When calculating the tumor uniformity index in step S2043, the difference in dose values ​​corresponding to the low volume fraction and the high volume fraction is obtained, and then the ratio of the dose value difference to the dose value corresponding to the median volume fraction is used as the tumor uniformity index. The smaller the tumor uniformity index is, the better the uniformity of the tumor is characterized. Optionally, the tumor uniformity index is obtained using the following formula: (5) Among them, HI is the tumor homogeneity index, D 1% is the dose value corresponding to the low volume fraction, D 50% is the dose value corresponding to the median volume fraction, D 99% is the dose value corresponding to the high volume fraction.

[0077] After obtaining the mean absorbed dose to the organ at risk and the tumor homogeneity index, the suitability assessment index is obtained as follows: (6) Among them, E c To evaluate the index, is the weight coefficient of the average absorbed dose, is the average absorbed dose, is the weight coefficient of the tumor homogeneity index, is the tumor homogeneity index. and When formulating a treatment plan, the therapist determines it based on the patient's actual situation. and The value range of is [0, 1], and . Optionally, and Determined based on historical data, such as through regression analysis.

[0078] In this way, the suitability evaluation index provided in the embodiment of the present application is compatible with the effects of neutron sources on organs at risk and tumors, and comprehensively evaluates the therapeutic effect of the neutron source scheme. The smaller the suitability evaluation index, the better the uniformity of the average absorbed dose of organs at risk and the absorbed dose of tumors, which means that the suitability of the neutron source is better. In this way, a neutron source suitability evaluation method for BNCT is constructed to analyze the advantages and disadvantages of the suitability of different neutron sources, providing a theoretical basis for formulating safe and effective treatment plans.

[0079] In addition, regarding the absorbed dose of the organs at risk, it should be noted that when it is confirmed that the maximum absorbed dose of any organ at risk in the target area is greater than or equal to the preset limit of the corresponding organ, it indicates that the current neutron source is not suitable. At this time, the treatment plan can also be evaluated.

[0080] In another example, Fig. 9 is a schematic diagram of an isodose curve in a CT image according to an exemplary embodiment.

[0081] After obtaining the equivalent dose of each voxel grid in the target area through the simulation results in step S203, an isodose curve is generated according to the equivalent dose of each voxel grid combined with the CT image of the target object. Fig. 9 As shown in the figure, the isodose curve connects points with the same percentage dose in a two-dimensional plane, and intuitively presents the distribution of points with the same dose. The isodose curve can not only accurately give the conformity of the dose distribution to the target area in the CT image and the uniformity of the dose distribution in the target area, but also depict the dose gradient around the target area and nearby organs at risk. It provides a more intuitive display method for evaluating different neutron sources.

[0082] In summary, Fig.10 is a flow chart of a method for evaluating the suitability of a neutron source for BNCT according to another exemplary embodiment, Fig.10 , the implementation process of the overall method is as follows: Read the CT image information of the target object, and define the tissue type and density information according to the CT value of each pixel in the CT image. Build a three-dimensional model based on the CT image, and create an RTSTRUCT file containing the target area contour information according to the target area (ROI) outlined by 3D Slicer in the CT image. Obtain the ROI contour information by parsing the RTSTRUCT file, and then determine the boundary conditions of the target area. Perform voxel grid matching in the three-dimensional model based on the boundary conditions to determine whether the voxel grid meets the boundary conditions of the target area. In other words, determine whether the voxel grid is inside or outside the target area.

[0083] When the voxel grid is judged to be outside the target area, the material group information and boron concentration of the voxel grid are determined according to the CT value. When the voxel grid is judged to be within the target area, the boron concentration-time curve is simulated in combination with the pharmacokinetic method to determine the material group information and boron concentration of the voxel grid according to the type of the target area.

[0084] Based on the material group information and boron concentration determined above, the simulation data required for Monte Carlo simulation (i.e., material card, grid cell card, lattice card, input card) are updated. At the same time, Monte Carlo simulation is performed in combination with the simulation data of the neutron source. The dose rate of the tumor and tissue is determined through Monte Carlo simulation. The radiation time (i.e., treatment time) is determined based on the prescribed dose and the tumor dose rate of the neutron source to be determined. Furthermore, the dose of the tumor and the organ at risk is obtained based on the treatment time.

[0085] Data processing is performed based on the dose of the tumor and organs at risk to obtain isodose curves and DVH maps, and the average absorbed dose is further obtained based on the DVH map. and the tumor homogeneity index HI, which is ultimately based on the mean absorbed dose The treatment suitability evaluation index Ec is obtained by combining the tumor uniformity index HI. Neutron source evaluation is performed based on the treatment suitability evaluation index Ec to determine the optimal neutron source and clarify the treatment plan.

[0086] In summary, the method provided in the embodiment of the present application combines the individual differences of different individuals, optimizes the accuracy of Monte Carlo simulation data according to individual pharmacokinetic characteristics, and accurately reflects the actual situation of the target object through Monte Carlo simulation. In addition, the method takes into account the evaluation of tumor uniformity and organ-at-risk hazard, realizes a reasonable evaluation of the treatment effects of different neutron sources, provides a theoretical basis for the formulation of a reasonable plan, and solves the defect of the prior art that the treatment plan cannot be evaluated.

[0087] In a second aspect, corresponding to the first aspect, an embodiment of the present application provides a neutron source suitability assessment device for BNCT. Fig.11 is a block diagram of a neutron source suitability assessment device for BNCT according to an exemplary embodiment. Fig.11 As shown, the device package is used to evaluate different neutron source treatment options, including: A construction module 901 is used to construct a three-dimensional model according to the CT image of the target object and determine the target area in the three-dimensional model; A determination module 902 is used to obtain the material group and boron concentration of each voxel grid in the three-dimensional model, and determine Monte Carlo simulation data based on the distribution of the voxel grid; An acquisition module 903 is used to perform Monte Carlo simulation according to Monte Carlo simulation data and simulation parameters of the neutron source, and obtain the equivalent dose of each voxel grid in the target area through the simulation results; The evaluation module 904 is used to determine the average absorbed dose and tumor homogeneity index of each organ at risk in the target area based on the equivalent dose of the voxel grid, and obtain the applicability evaluation index according to the average absorbed dose and the tumor homogeneity index.

[0088] Optionally, the evaluation module obtains the applicability evaluation index according to the average absorbed dose and the uniformity index in the following manner:

[0089] Among them, Ec is the applicability evaluation index, is the weight coefficient of the average absorbed dose, is the average absorbed dose, is the weight coefficient of the tumor homogeneity index, Tumor homogeneity index.

[0090] Optionally, the evaluation module includes: A first determining unit, configured to obtain a dose volume histogram according to an equivalent dose of each voxel grid in the target area; A second determination unit is used to determine dose absorption data of each organ at risk and tumor in the target area according to the dose volume histogram; The third determination unit is used to determine an average absorbed dose based on the dose absorption data of each organ at risk and the equivalent dose of the voxel grid in the organ at risk, and to determine a tumor homogeneity index according to the dose absorption data of the tumor.

[0091] Optionally, the dose absorption data of each organ at risk includes the maximum absorbed dose of each organ at risk; and the third determination unit is specifically configured to: In response to the maximum absorbed doses of all organs at risk being less than preset limits of the corresponding organs, the absorbed dose of the organ at risk is obtained according to the equivalent dose of the voxel grid in any organ at risk, and the average absorbed dose is obtained according to the absorbed doses of all organs at risk.

[0092] The dose absorption data of each organ at risk includes the maximum absorbed dose of each organ at risk; the device further includes: The fourth determination unit is configured to indicate that the treatment plan including the current neutron source does not meet the treatment condition in response to the maximum absorbed dose of any of the organs at risk being greater than or equal to a preset limit value. At this time, subsequent steps such as obtaining the tumor homogeneity index are no longer required, and the neutron source can be determined to be unsuitable without obtaining the suitability evaluation index.

[0093] Optionally, the dose absorption data of the tumor includes dose values ​​corresponding to a low volume fraction, a median volume fraction, and a high volume fraction, and the third determination unit is specifically used to: Obtaining a dose value difference corresponding to the low volume fraction and the high volume fraction; The ratio of the dose value difference to the dose value corresponding to the median volume fraction is used as the tumor uniformity index.

[0094] Optionally, the simulation result includes a dose rate of a target component in any voxel grid, and the target component includes boron, nitrogen, hydrogen and photons; and the acquisition module includes: a fifth determination unit, configured to perform equivalent dose processing on the dose rate of the target component to obtain a total dose rate of the voxel grid; A first acquisition unit is used to acquire the radiation duration according to the prescription dose and the total dose rate of the voxel grid in the tumor area in the target area; The second acquisition unit is used to acquire the equivalent dose of each voxel grid according to the radiation duration and the total dose rate.

[0095] Optionally, when the fifth unit performs equivalent dose processing on the dose rate of the target component to obtain the total dose rate of the voxel grid, it is performed according to the following formula:

[0096] Where D is the total dose rate, DB,ppm is the boron dose rate, DN is the nitrogen dose rate, DH is the hydrogen dose rate, and Dγ is the photon dose rate; CBE is the composite biological effect factor, RBEN is the relative biological effect factor determined based on the nitrogen absorption dose rate, RBEH is the relative biological effect factor determined based on the hydrogen absorption dose rate, and RBEγ is the relative biological effect factor determined based on the photon absorption dose rate; Represents the time-dependent boron concentration in tissues.

[0097] Optionally, the determining module includes: A judging unit, used to judge whether the current voxel grid is within the target area; A first determination unit, configured to, when the determination unit determines that the current voxel grid is within the target region, obtain a corresponding material group according to the position of the current voxel grid in the target region, and determine a boron concentration corresponding to the material group according to the pharmacokinetic characteristics of the boron drug of the target object; The second determination unit is used to determine the material group of the voxel grid according to the CT value of the CT image corresponding to the voxel grid if the judgment unit determines that the current voxel grid is outside the target area, and determine the relative boron concentration based on the material category.

[0098] Optionally, the device further includes: an acquisition module.

[0099] The acquisition module is used to perform pharmacokinetic simulation based on boron drug data and individual physiological parameters of the target object to obtain pharmacokinetic curves in different material groups; The pharmacokinetic characteristics of the corresponding tissue category are obtained according to the pharmacokinetic curve.

[0100] It should be noted that the boron neutron capture therapy scheme evaluation device provided in this embodiment is used to implement the above-mentioned implementation mode, and the descriptions that have been made will not be repeated. As used above, the terms "module", "unit", "subunit" and the like can implement a combination of software and / or hardware for a predetermined function. Although the device described in the above embodiment is preferably implemented in software, the implementation of hardware, or a combination of software and hardware, is also possible and conceivable.

[0101] In a third aspect, an embodiment of the present application provides an electronic device, Fig.12 FIG. 1 is a block diagram of an electronic device according to an exemplary embodiment. Fig.12 As shown, the electronic device may include a processor 81 and a memory 82 storing computer program instructions.

[0102] Specifically, the processor 81 may include a central processing unit (CPU), or an application specific integrated circuit (ASIC), or may be configured to implement one or more integrated circuits of the embodiments of the present application.

[0103] Among them, the memory 82 may include a large-capacity memory for data or instructions. By way of example and not limitation, the memory 82 may include a hard disk drive (HDD), a floppy disk drive, a solid-state drive (SSD), a flash memory, an optical disk, a magneto-optical disk, a magnetic tape, or a universal serial bus (USB) drive, or a combination of two or more of these. Where appropriate, the memory 82 may include a removable or non-removable (or fixed) medium. Where appropriate, the memory 82 may be inside or outside the data processing device. In a specific embodiment, the memory 82 is a non-volatile memory. In a specific embodiment, the memory 82 includes a read-only memory (ROM) and a random access memory (RAM). Where appropriate, the ROM may be a mask-programmed ROM, a programmable ROM (PROM), an erasable PROM (EPROM), an electrically erasable PROM (EEPROM), an electrically alterable ROM (EAROM) or a flash memory (FLASH), or a combination of two or more of these. Under appropriate circumstances, the RAM can be a static random access memory (SRAM) or a dynamic random access memory (DRAM), wherein the DRAM can be a fast page mode dynamic random access memory (FPMDRAM), an extended data output dynamic random access memory (EDODRAM), a synchronous dynamic random access memory (SDRAM), etc.

[0104] The memory 82 may be used to store or cache various data files required for processing and / or communication, as well as possible computer program instructions executed by the processor 81 .

[0105] The processor 81 reads and executes the computer program instructions stored in the memory 82 to implement the process of the boron neutron capture therapy scheme evaluation method described in the above embodiment.

[0106] In one embodiment, the electronic device may further include a communication interface 83 and a bus 80. Fig.12 As shown, the processor 81, the memory 82, and the communication interface 83 are connected via a bus 80 and communicate with each other.

[0107] The communication interface 83 is used to implement communication between the modules, devices, units and / or equipment in the embodiment of the present application. The communication port 83 can also implement data communication with other components such as: external devices, image / data acquisition equipment, databases, external storage, and image / data processing workstations.

[0108] The bus 80 includes hardware, software or both, and couples the components of the electronic device to each other. The bus 80 includes but is not limited to at least one of the following: a data bus, an address bus, a control bus, an expansion bus, and a local bus. By way of example and not limitation, bus 80 may include an Accelerated Graphics Port (AGP) or other graphics bus, an Extended Industry Standard Architecture (EISA) bus, a Front Side Bus (FSB), a Hyper Transport (HT) interconnect, an Industry Standard Architecture (ISA) bus, an InfiniBand interconnect, a Low Pin Count (LPC) bus, a memory bus, a Micro Channel Architecture (MCA) bus, a Peripheral Component Interconnect (PCI) bus, a PCI-Express (PCI-X) bus, a Serial Advanced Technology Attachment (SATA) bus, a Video Electronics Standards Association Local Bus (VLB) bus, or other suitable buses or a combination of two or more of these. Where appropriate, bus 80 may include one or more buses. Although embodiments of the present application describe and illustrate a particular bus, the present application contemplates any suitable bus or interconnect.

[0109] In a fourth aspect, an embodiment of the present application provides a computer-readable storage medium having a program stored thereon, and when the program is executed by a processor, the neutron source suitability assessment method for BNCT provided in the first aspect is implemented.

[0110] The readable storage medium may include but is not limited to: a portable disk, a hard disk, a random access memory, a read-only memory, an erasable programmable read-only memory, an optical storage device, a magnetic storage device or any suitable combination of the above.

[0111] In a possible embodiment, the present invention can also be implemented in the form of a program product, which includes a program code. When the program product is run on a terminal device, the program code is used to enable the terminal device to execute the steps of the neutron source suitability assessment method for BNCT provided in the first aspect.

[0112] The program code for executing the present invention may be written in any combination of one or more programming languages, and may be executed entirely on a user device, partially on a user device, as an independent software package, partially on a user device and partially on a remote device, or entirely on a remote device.

[0113] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0114] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims.

Claims

1. A method for evaluating the suitability of neutron sources for BNCT. It is characterized in that The method comprises: constructing a three-dimensional model based on the CT image of the target object, and determining a target area in the three-dimensional model; Obtaining the material group and boron concentration of each voxel grid in the three-dimensional model, and determining Monte Carlo simulation data in combination with the distribution of the voxel grid; Performing Monte Carlo simulation according to the Monte Carlo simulation data and simulation parameters of the neutron source, and obtaining the equivalent dose of each voxel grid in the target area through the simulation result; The average absorbed dose and the tumor homogeneity index of all organs at risk in the target area are determined based on the equivalent dose of the voxel grid, and the suitability assessment index is obtained according to the average absorbed dose and the tumor homogeneity index.

2. The evaluation method according to claim 1, It is characterized in that The obtaining of the applicability evaluation index according to the average absorbed dose and the uniformity index is performed in the following manner: Among them, E c To evaluate the index, is the weight coefficient of the average absorbed dose, is the average absorbed dose, is the weight coefficient of the tumor homogeneity index, Tumor homogeneity index.

3. The evaluation method according to claim 1, It is characterized in that The determining of the average absorbed dose of all organs at risk and the tumor homogeneity index in the target area based on the equivalent dose of the voxel grid comprises: Obtaining a dose volume histogram according to the equivalent dose of each voxel grid in the target area; Determining dose absorption data of each organ at risk and tumor in the target area according to the dose volume histogram; The average absorbed dose is determined based on the dose absorption data of each organ at risk and the equivalent dose of a voxel grid in the organ at risk, and the tumor homogeneity index is determined according to the dose absorption data of the tumor.

4. The evaluation method according to claim 3, It is characterized in that The dose absorption data of each organ at risk includes the maximum absorbed dose of each organ at risk; and determining the average absorbed dose according to the dose absorption data of each organ at risk includes: In response to the maximum absorbed doses of all the organs at risk being less than the preset limit of the corresponding organ, the absorbed dose of the organ at risk is obtained according to the equivalent dose of the voxel grid in any of the organs at risk, and the average absorbed dose is obtained according to the absorbed doses of all the organs at risk.

5. The evaluation method according to claim 3, It is characterized in that The dose absorption data of the tumor includes dose values ​​corresponding to a low volume fraction, a median volume fraction, and a high volume fraction. Determining the tumor uniformity index according to the dose absorption data of the tumor includes: Obtaining a dose value difference corresponding to the low volume fraction and the high volume fraction; The ratio of the dose value difference to the dose value corresponding to the median volume fraction is used as the tumor uniformity index.

6. The evaluation method according to claim 1, It is characterized in that The simulation results include dose rates of target species in any voxel grid, the target species including boron, nitrogen, hydrogen and photons; The step of obtaining the equivalent dose of each voxel grid in the target area through simulation results includes: Performing equivalent dose processing on the dose rate of the target component to obtain a total dose rate of the voxel grid; Obtaining radiation duration according to the prescription dose and the total dose rate of the voxel grid in the tumor region of the target region; The equivalent dose of each voxel grid is acquired according to the radiation duration and the total dose rate.

7. The evaluation method according to claim 6, It is characterized in that The dose rate of the target component is subjected to equivalent dose processing to obtain the total dose rate of the voxel grid, according to the following formula: Where D is the total dose rate, D B,ppm is the dose rate per unit boron concentration, D N is the nitrogen dose rate, D H is the hydrogen dose rate, D γ is the photon dose rate; CBE is a composite biological effector, RBE N is the relative biological effect factor determined based on the nitrogen absorbed dose rate, RBE H is the relative biological effect factor determined based on the hydrogen absorption dose rate, RBE γ is the relative biological effect factor determined based on the photon absorbed dose rate; Represents the time-dependent boron concentration in tissues.

8. The evaluation method according to claim 1, It is characterized in that Obtaining the material group class and boron concentration of each voxel grid in the three-dimensional model, including: Determine whether the current voxel grid is within the target area; If it is in the target area, obtaining the corresponding material group according to the position of the current voxel grid in the target area, and determining the boron concentration corresponding to the material group according to the pharmacokinetic characteristics of the boron drug in the material group; If it is outside the target area, the material group of the voxel grid is determined according to the CT value of the CT image corresponding to the voxel grid, and the relative boron concentration is determined based on the material group.

9. The evaluation method according to claim 8, It is characterized in that The method further comprises: Perform pharmacokinetic simulation based on boron drug data and individual physiological parameters of target subjects to obtain pharmacokinetic curves in different material groups; The pharmacokinetic characteristics of the corresponding tissue category are obtained according to the pharmacokinetic curve.

10. A neutron source suitability assessment device for BNCT, It is characterized in that The device comprises: A construction module, used to construct a three-dimensional model according to the CT image of the target object, and determine the target area in the three-dimensional model; A determination module, used to obtain the material group and boron concentration of each voxel grid in the three-dimensional model, and determine Monte Carlo simulation data in combination with the distribution of the voxel grid; An acquisition module, used for performing Monte Carlo simulation according to the Monte Carlo simulation data and simulation parameters of the neutron source, and obtaining the equivalent dose of each voxel grid in the target area through the simulation result; An evaluation module is used to determine the average absorbed dose and the tumor uniformity index of each organ at risk in the target area based on the equivalent dose of the voxel grid, and to obtain a suitability evaluation index according to the average absorbed dose and the tumor uniformity index.

11. An electronic device, It is characterized in that The electronic device comprises: Memory, processor, and A computer program stored in the memory and executable on the processor, wherein when the processor executes the computer program, the method for evaluating the suitability of a neutron source for BNCT according to any one of claims 1 to 9 is implemented.

12. A computer-readable storage medium having a computer program stored thereon, It is characterized in that When the program is executed by a processor, the method for evaluating the suitability of a neutron source for BNCT according to any one of claims 1 to 9 is implemented.

Citation Information

Patent Citations

  • Biological dose calculation method for boron neutron capture therapy

    CN112618970A

  • Boron neutron capture therapy system and irradiation parameter selection method thereof

    CN116603176A

  • Determining uncertainty in radiation therapy delivered dose accumulation

    US20230310896A1

Cited By

  • Compton camera image reconstruction method and device, computer equipment and storage medium

    CN120219551A